As we advance our groundbreaking platform toward clinical development, we are so excited that Tay Salimullah has joined our Board of Directors, his first Board appointment since leaving Novartis Gene Therapies. His expertise spans drug development, pricing science, market access, and operational excellence in high-value healthcare solutions.? https://lnkd.in/eGJqM5H8 #CancerResearch #Glioblastoma #Immunotherapy #GeneTherapy #SyntheticBiology #LifeSciences #Innovation #Appointment
关于我们
- 网站
-
https://www.trogenixbio.com
Trogenix的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 类型
- 私人持股
Trogenix员工
动态
-
We are excited to announce that Trogenix has emerged from stealth today, unveiling our breakthrough Synthetic Super-Enhancer (SSE) platform, Odysseus, for treating aggressive cancers: https://lnkd.in/eGJqM5H8 Founded by our CSO Steve Pollard and 4BIO Capital as a spinout from The University of Edinburgh, and led by CEO Ken Macnamara, Trogenix brings together synthetic biology, machine learning, gene therapy and precision targeting technologies to transform cancer treatment, from chronic disease management to potentially curative one-time treatments. Thank you to our investors 4BIO Capital, IQ Capital, Cancer Research Horizons, National Brain Tumor Society, AIN Ventures and Old College Capital for their support in our mission to revolutionise cancer treatment. #CancerResearch #Glioblastoma #Immunotherapy #GeneTherapy #SyntheticBiology #LifeSciences #Innovation